The FDA is developing several structures and a broad group of experts across disciplines to help craft artificial intelligence policy. But the proliferation of AI-related initiatives raises the question of who, ultimately, will make decisions about when novel applications of AI are acceptable.
The growing number of AI experts at the FDA could lead to policy consistency questions. • Source: Shutterstock
When it comes to developing artificial intelligence policy, the US Food and Drug Administration has a broad base of staff expertise to use.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
